Clinical Trials Directory

Trials / Unknown

UnknownNCT03264807

Lymph Node 14v Dissection in Clinical Stage T3N+, T4N+ of Gastric Cancer

A Multicenter Randomized Controlled Trial of D2 Versus D2 + Lymph Node 14v Dissection in Clinical Stage T3N+, T4N+ of Gastric Cancer (14VIGTORY Trial)

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
518 (estimated)
Sponsor
National Cancer Center, Korea · Other Government
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection.

Detailed description

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection. Actually, if the 14v lymph node metastasis is suspected before surgery, it is excluded from the study. In a retrospective study conducted in our hospital, we compared the patients with the 14v lymphadenectomy group and those without the 14v lymphadenectomy group, the survival rate of the 14v lymphadenectomy group was 11% higher than that of the 14v non-lymphadenectomy group.Previous studies have suggested that the presence of metastatic lymph nodes in the 14v lymph node is not good and that removal of the 14v lymph node does not affect prognosis. However, if the lymph node is a continuous tissue and the transition to the 14v lymph node is confirmed microscopically, a negative prognosis may be expected because it is likely that the cancer has spread to the distal lymph node. In addition, inadequate resection of the lymphatic or 14v lymph node adjacent to the 14v lymph node in the absence of evidence of metastasis of the 14v lymph node under microscopic examination indicates that cancer may spread even after curative surgery, To prevent cancer metastasis.

Conditions

Interventions

TypeNameDescription
PROCEDURED2 lymphadenectomySubtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
PROCEDURED2 and #14v lymphadenectomySubtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.

Timeline

Start date
2015-08-06
Primary completion
2020-12-30
Completion
2021-12-31
First posted
2017-08-29
Last updated
2020-03-03

Locations

12 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03264807. Inclusion in this directory is not an endorsement.